Board of directors

PartnerRe Ltd. Declares Dividend on Preferred Shares

Retrieved on: 
Friday, May 20, 2022
Professional Services, Insurance, Finance, Insurance, Solution, Board, Life, National Organization of Life and Health Insurance Guaranty Associations, P&C, Board of directors, Health

PartnerRe Ltd. announced that its Board of Directors has declared a dividend for the period March 15, 2022 June 14, 2022 of $0.3046875 per share on the Companys 4.875% Fixed Rate Non-Cumulative Redeemable Preferred Shares, Series J.

Key Points: 
  • PartnerRe Ltd. announced that its Board of Directors has declared a dividend for the period March 15, 2022 June 14, 2022 of $0.3046875 per share on the Companys 4.875% Fixed Rate Non-Cumulative Redeemable Preferred Shares, Series J.
  • The dividend is payable on June 15, 2022 to shareholders of record on May 31, 2022.
  • PartnerRe Ltd. is a leading global reinsurer that helps insurance companies reduce their earnings volatility, strengthen their capital and grow their businesses through reinsurance solutions.
  • At March 31, 2022, total assets were $28.4 billion, total capital was $8.7 billion and total shareholders equity was $6.8 billion.

Macellum Issues Statement Regarding the Kohl’s Board’s Apparent Breach of Fiduciary Duty and Failure to Disclose Material Information Prior to 2022 Annual Meeting

Retrieved on: 
Friday, May 20, 2022
Retail, Professional Services, Department Stores, Finance, Company, Partner (business rank), KSS, Leadership, News, Macy, Inc., Board, Macellum, Institutional Shareholder Services, Board of directors, Sale, Acquisition, LLC, Bed, NYSE, L Brands, Macy's, Management

Under the right oversight and leadership that has sufficient expertise and a viable strategy, we firmly believe Kohls will consistently deliver superior operating and financial results.

Key Points: 
  • Under the right oversight and leadership that has sufficient expertise and a viable strategy, we firmly believe Kohls will consistently deliver superior operating and financial results.
  • It was alarming to learn yesterday that the current Board appears to have withheld material information from shareholders about the state of Kohls in the lead-up to this years pivotal annual meeting.
  • If any of the current directors were aware of this material information prior to the annual meeting, their involvement in any decision to withhold the news prior to a monumental shareholder vote suggests to us a clear breach of fiduciary duty.
  • Either way, Kohls should immediately appoint three of our nominees including a shareholder representative from Macellum to the Board to replace three long-serving incumbents.

Shore Capital Partners Announces Partnership with AA Medical

Retrieved on: 
Friday, May 20, 2022
Banking, Practice Management, Physical Therapy, Professional Services, Other Health, Health, General Health, Medical Devices, Hospitals, Surgery, Finance, Physician, Real estate, Food, APriori Capital Partners, Surgeon, Endoscopy, Multimedia, Investment, Solution, Health, Marketing, Health care, Elective surgery, Industry, Partnership, AA, Board, Technology, Board of directors, Corporate services, Growth, Risk management

Shore Capital Partners (Shore or Shore Capital) is pleased to announce it has completed a partnership with AA Medical, a provider of sustainable solutions to both the new and resale medical device equipment markets based in Mokena, Illinois, with a second location in Miami, Florida.

Key Points: 
  • Shore Capital Partners (Shore or Shore Capital) is pleased to announce it has completed a partnership with AA Medical, a provider of sustainable solutions to both the new and resale medical device equipment markets based in Mokena, Illinois, with a second location in Miami, Florida.
  • AA Medical partners with equipment manufacturers, banks, and medical facilities to buy pre-owned equipment, unlocking the residual value to help facilities maximize resources to improve patient care and optimize clinical asset purchases.
  • To support AA Medicals growth, Shore has assembled a talented Board of Directors led by Don Pierce, Partner at Shore Capital.
  • AA Medical has maintained their dedication to excellence in supplying high quality medical equipment to customers across the world, said Mr. Pierce.

NYC REIT Sends Letter Urging Shareholders to Vote for Company’s Incumbent Director Nominee as Annual Meeting Approaches

Retrieved on: 
Friday, May 20, 2022
Construction & Property, Professional Services, REIT, Finance, ARE, COVID-19, No, Telephone, Gold, Annual general meeting, Beneficial ownership, Lois, 1969–70 1. Slovenská národná hokejová liga season, Total return, Internet, ESRT, Investor relations, REIT, VNO, SLG, Times Square, Board, Bronx Community Board 12, NYSE, Lead, Board of directors, ALL, SEC, GOLD, Annual Meetings of the International Monetary Fund and the World Bank Group, Letter, Financial services, Holding company, Self storage, Real estate, Auction, Security (finance), Ownership

NYC strongly encourages all shareholders to vote on the GOLD proxy card FOR the reelection of Elizabeth Tuppeny and protect their investment.

Key Points: 
  • NYC strongly encourages all shareholders to vote on the GOLD proxy card FOR the reelection of Elizabeth Tuppeny and protect their investment.
  • Further, NYC advises shareholders discard the white proxy card that they may receive from Comrit.
  • NYC has paid an attractive $0.40 per share annual dividend, even during the harsh times of the Covid-19 pandemic.
  • The total value that has been created under Ms. Tuppenys as lead independent director of the Board is truly exceptional.

Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal

Retrieved on: 
Friday, May 20, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Engineering, Company, HER2, Wilson Sonsini Goodrich & Rosati, U.S. Securities and Exchange Commission, Chair, Director, Patient, News, COVID-19, Inc., Completeness, Research, Scooby-Doo! Mask of the Blue Falcon, Workforce, LLP, IND, Forward-looking statement, Board, Safety, Board of directors, Drug development, Conjugation, Security (finance), Blake, Cassels & Graydon, Private Securities Litigation Reform Act, Twitter, One Piece, NYSE, Letter, CEO, Fine chemical, Renewable energy, Pharmaceutical industry, Medical imaging, Zymeworks

Following a comprehensive review of the unsolicited, opportunistic, non-binding proposal, including independent analyses completed by external financial advisors engaged by Zymeworks, the Board of Directors has determined that the proposal significantly undervalues its prospects related to the Companys long-term business strategy and potential commercial opportunities.

Key Points: 
  • Following a comprehensive review of the unsolicited, opportunistic, non-binding proposal, including independent analyses completed by external financial advisors engaged by Zymeworks, the Board of Directors has determined that the proposal significantly undervalues its prospects related to the Companys long-term business strategy and potential commercial opportunities.
  • As a result, the Board of Directors of Zymeworks has determined that it would not be appropriate to enter into discussions in response to the current proposal at a price of $10.50 per share.
  • Lota Zoth, Zymeworks Lead Independent Director, commented, We welcome constructive engagement with, and input from, all of our shareholders.
  • On April 28, 2022, the Company received an unsolicited, non-binding proposal from All Blue, which revealed its 5.9% stake in Zymeworks.

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

Retrieved on: 
Friday, May 20, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Degenerative disease, International, Nasdaq, Doctor of Philosophy, Drug discovery, Periodontal disease, Patient, United Nations University International Institute for Software Technology, McCoy, Drug design, Â, NIH, Method, Research, ACS Award in Pure Chemistry, National, Board, University, American Chemical Society, Board of directors, AACR Awards, Brigham Young University, Therapy, Twitter, Acquisition, ACS, University of California, San Diego Performance-Based Skills Assessment, Bone, Pharmaceutical industry, Biochemistry, Purdue University, Chemistry

In conjunction with todays acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Lows caliber to our Board of Directors, said David Lamond, chairman of Cortexymes Board of Directors.

Key Points: 
  • In conjunction with todays acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Lows caliber to our Board of Directors, said David Lamond, chairman of Cortexymes Board of Directors.
  • The Cortexyme team and I share the same passion for challenging the status quo to deliver breakthrough therapeutics, said Dr. Philip Low.
  • Dr. Philip S. Low is the Presidential Scholar in Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.
  • Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases.

Polygon Debuts to Help Increase Access to Remote Learning Differences Evaluations and Support

Retrieved on: 
Friday, May 20, 2022
General Health, Health, Mental Health, Other Education, Technology, Primary, Secondary, Education, Other Technology, MBA, Education, UC, Summer learning loss, Spark Capital, Director, Creativity, Multimedia, Dyslexia, Learning, Research, Biomedical engineering, LDS, Brain, Industry, Life, Child, Meryl Silverburgh, Student, ADHD, BCG, Technology, Board of directors, Adoption, Diagnosis, University of California, Berkeley, Video game, Polygon

Polygon , a company specializing in remote evaluations and support for dyslexia, ADHD, and other learning differences, today announced that it closed a $3.6 million investment led by Spark Capital .

Key Points: 
  • Polygon , a company specializing in remote evaluations and support for dyslexia, ADHD, and other learning differences, today announced that it closed a $3.6 million investment led by Spark Capital .
  • Further platform development, additional services, and national expansion will help us provide gold-standard learning differences services to the mass market."
  • Polygon provides remote evaluations and support for dyslexia, ADHD, and other learning differences with targeted psychoeducational and comprehensive Neuropsychological assessments.
  • Polygon is a new kind of psychology practice specializing in evaluations and support for dyslexia, ADHD, and other learning differences.

KKR Leads $200+ Million Growth Investment in Enterprise Identity Protection Leader Semperis

Retrieved on: 
Tuesday, May 24, 2022
Technology, Networks, Data Management, Security, Cloud, Financial Times, General partnership, Partner, Multimedia, Goal, Azure AD Connect, Active Directory, AD, Research, KKR, Industry, Partnership, Crime, Board, Finance, Technology, Inc. (magazine), Board of directors, Time, Organization, Gartner, Microsoft, Insight Partners, Directory, Frost & Sullivan, Risk management, Medical device, Video game, Atrophaneura semperi

With Semperis' multi-layered identity protection, organizations can fend off cyber attacks without being forced to choose between two bad options: paying the criminals or getting shut down.

Key Points: 
  • With Semperis' multi-layered identity protection, organizations can fend off cyber attacks without being forced to choose between two bad options: paying the criminals or getting shut down.
  • KKR is investing in Semperis through its Next Generation Technology Growth Fund II, a fund dedicated to growth equity investment opportunities in the technology space.
  • Semperis' leading identity protection technology and incident response expertise are delivering category-defining innovation, and KKR is proud to back their mission."
  • Semperis hosts the award-winning Hybrid Identity Protection conference and podcast series ( www.hipconf.com ) and built the free Active Directory security assessment tool, Purple Knight ( www.purple-knight.com ).

Carter’s, Inc. Announces Quarterly Dividend

Retrieved on: 
Friday, May 20, 2022
Parenting, Children, Family, Baby, Maternity, Consumer, Fashion, Retail, Department Stores, Company, Walmart, CRI, Child, Board of directors, Oshkosh, Board, East Coast hip hop, Target, NYSE, Toy, Amazon

The Board of Directors of Carters, Inc. (NYSE:CRI) today declared a quarterly dividend of $0.75 per share, payable on June 10, 2022, to shareholders of record at the close of business on May 31, 2022.

Key Points: 
  • The Board of Directors of Carters, Inc. (NYSE:CRI) today declared a quarterly dividend of $0.75 per share, payable on June 10, 2022, to shareholders of record at the close of business on May 31, 2022.
  • Future declarations of quarterly dividends and the establishment of future record and payment dates will be at the discretion of the Board based on a number of factors, including the Companys future financial performance and other considerations.
  • Carters, Inc. is the largest branded marketer in North America of apparel exclusively for babies and young children.
  • The Company owns the Carters and OshKosh Bgosh brands, two of the most recognized brands in the marketplace.

Molson Coors Beverage Company Announces Regular Quarterly Dividend

Retrieved on: 
Thursday, May 19, 2022
Retail, Food, Beverage, Wine & Spirits, People, Social Security Government Pension Offset, Form, Biophysical environment, Coors Light, Carbonated water, Electric Bond and Share Company v. Securities and Exchange Commission, Blue moon, Director, Environment, Molson Coors Beverage Company, Coors, Beer, TSX, U.S. Securities and Exchange Commission, Maharajkumar of Vizianagram, Board, Coors Brewing Company, Board of directors, MCCI, Twitter, Drink, NYSE, Social, Holding company, Molson Brewery, Carling Brewery

The quarterly dividend is payable to holders of Class A and Class B common stock of Molson Coors Beverage Company.

Key Points: 
  • The quarterly dividend is payable to holders of Class A and Class B common stock of Molson Coors Beverage Company.
  • In addition, the Board of Directors of Molson Coors Canada Inc. (TSX: TPX.B, TPX.A) today declared a quarterly dividend of approximately CDN$0.48 (the Canadian dollar equivalent of the dividend declared on Molson Coors Beverage Company stock), payable June 15, 2022, to its Class A and Class B exchangeable shareholders of record on June 3, 2022.
  • About Molson Coors Canada Inc.
    Molson Coors Canada Inc. (MCCI) is a subsidiary of Molson Coors Beverage Company.
  • MCCI Class A and Class B exchangeable shares offer substantially the same economic and voting rights as the respective classes of common shares of Molson Coors Beverage Company, as described in Molson Coors Beverage Companys annual proxy statement and Form 10-K filings with the U.S. Securities and Exchange Commission.